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Introduction
In mammalian cells, the nuclear factor κB (NFκB) family 
of transcription factors contains 5 members: RelA (p65), RelB, 
c-Rel, NFκB1 (p105/p50), and NFκB2 (p100/p52), which can 
induce or repress the expression of target genes by binding DNA 
as homo- or hetero-dimers.1,2 In unstimulated cells, the major-
ity of NFκB is found localized in the cytoplasm in an inactive 
complex with proteins from the IκB (inhibitors of the NFκB 
proteins) family, which includes IκBα, IκBβ, IκBγ, IκBε, and 
Bcl-3.1,2 Nuclear localization of NFκB complexes can be induced 
by various stimuli, including bacterial products, inflammatory 
cytokines, DNA damage, cell stress, viral proteins, and infection.2
In the classical (or canonical) NFκB pathway, stimuli such 
as inflammatory cytokines or toll-like receptor (TLR) ligands 
induce IκB kinase (IKK) complex activity.2 The core IKK 
complex consists of 2 catalytic subunits, IKKα (IKK1), IKKβ 
(IKK2), and a regulatory subunit NEMO (IKKγ). In the clas-
sical pathway, IKKβ-dependent IκB phosphorylation results in 
IκB degradation by the proteasome, leading to the activation of 
RelA- and c-Rel-containing NFκB complexes.2 The alternative 
(or non-canonical) NFκB pathway, induced by stimuli such as 
CD40 ligand and lymphotoxin β, involves activation of IKKα, 
which phosphorylates the p100 precursor, resulting in its prote-
asome-dependent processing to p52 and the nuclear localization 
of p52/RelB complexes.2 Many cancer cell lines and primary 
tumors contain deregulated NFκB, which can result from muta-
tion of upstream signaling components or oncogenic signaling, 
leading to an overactive IKK complex.3
The NFκB family is involved in the regulation of thousands of 
genes controlling various cellular processes, such as the immune 
and inflammatory responses, cell death or cell survival, stress 
responses, and cell adhesion and proliferation.1 NFκB activity 
and target genes are also linked to the cell cycle and prolifera-
tion. For example, NFκB can be required for the expression of 
the genes encoding Cyclin D1, Skp2, and c-Myc.4-9 This labora-
tory previously reported that in some cell lines, such as U2OS 
osteosarcoma cells, NFκB is absolutely required for cell prolif-
eration, and this is associated with regulation of these gene tar-
gets.6,7 A common theme with these target genes is their ability 
to be regulated by p52 containing NFκB complexes. Cyclin D1 
is one of the best-known NFκB target genes involved in cell cycle 
regulation during G
1
 phase,7 and its expression is regulated by 
p52 in co-operation with Bcl-3 and RelA.6,7 Skp2, which can also 
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Activation of the NFκB signaling pathway allows the cell to respond to infection and stress and can affect many cel-
lular processes. As a consequence, NFκB activity must be integrated with a wide variety of parallel signaling pathways. 
one mechanism through which NFκB can exert widespread effects is through controlling the expression of key regula-
tory kinases. Here we report that NFκB regulates the expression of genes required for centrosome duplication, and that 
polo-like kinase 4 (pLK4) is a direct NFκB target gene. RNA interference, chromatin immunoprecipitation, and analysis of 
the pLK4 promoter in a luciferase reporter assay revealed that all NFκB subunits participate in its regulation. Moreover, 
we demonstrate that NFκB regulation of pLK4 expression is seen in multiple cell types. Significantly long-term deletion of 
the NFκB2 (p100/p52) subunit leads to defects in centrosome structure. this data reveals a new component of cell cycle 
regulation by NFκB and suggests a mechanism through which deregulated NFκB activity in cancer can lead to increased 
genomic instability and uncontrolled proliferation.
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be regulated by p52,7,10 promotes the degradation of the CDK 
inhibitor p27, allowing cell cycle progression5. c-Myc promotes 
proliferation and can be regulated by the RelB/p52 heterodi-
mer4 and other p52 complexes.7 However, many different NFκB 
complexes can participate in regulation of these genes, and our 
own data suggests a complex pattern of activation and repression, 
dependent upon cell cycle stage.7
These studies have focused on the role of NFκB in the tran-
sition through G
1
 phase of the cell cycle, and relatively little is 
known about any potential role in inducing G
2
 phase gene expres-
sion or regulation of mitosis. However, such a role was implied 
by analysis of cells following depletion of p100/p52 by siRNA, 
which in addition to a G
1
 arrest also resulted in an increase 
of cells in G
2
/M phase.6 Furthermore, IKK activity has been 
directly linked with mitotic events. For example, IKKα can phos-
phorylate Aurora A,11 while IKKβ has a role in bipolar spindle 
assembly.12 In this manuscript we therefore investigated the abil-
ity of p52 and other NFκB subunits to regulate genes required for 
mitosis and have identified Polo-like kinase 4 (PLK4) as a bona 
fide NFκB target gene.
PLK4 is an atypical member of the Polo-like kinase family 
and a key regulator of centriolar duplication.13 Overexpression of 
PLK4 induces over-amplification of centrosomes, while depletion 
reduces centriole number.14-17 PLK4 works in concert with the 
cyclin-dependent kinase CDK2, CP110, and the PLK4 down-
stream regulator spindle assembly 6 homolog (SAS6) to ensure 
correct centrosome duplication in S-phase.15 Although some 
studies link PLK4 expression to p53 activity,18-21 the factors con-
trolling transcriptional regulation of the PLK4 gene expression 
have largely not been identified. Here we reveal PLK4 as a new 
NFκB target gene, providing a direct link between NFκB activ-
ity and centrosome duplication, with implications for the role of 
these transcription factors in tumorigenesis.
Results
NFκB2 (p100/p52)-dependent regulation of cell cycle gene 
expression
Although U2OS cells require NFκB2 gene expression, which 
encodes the p100/p52 NFκB subunit, to proliferate in vitro,6 our 
understanding of the gene targets involved in this process is lim-
ited. We therefore wished to extend these studies to determine any 
effects of this protein on target genes involved in different aspects 
of cell cycle progression. NFκB2 siRNA depletion was therefore 
performed in U2OS cells. Propidium iodide staining and subse-
quent FACs analysis confirmed reduced numbers of S phase cells 
(Fig. 1A and not shown), consistent with data described previ-
ously in this laboratory.6 As expected, this was associated with 
downregulation of Cyclin D1 mRNA and protein levels (Fig. 1B 
and C). We also observed effects on other cell cycle regulators, 
including a strong depletion of CDK4 expression. This effect was 
confirmed in untransformed human dermal fibroblasts (Alessio 
Iannetti and Neil Perkins, unpublished observations), and could 
contribute to the increased numbers of G
1
 phase cells (Fig. 1A). 
CDK1 and Cyclin B1 protein levels were largely unaffected by 
the NFκB2 siRNA (Fig. 1C). However, no significant effect on 
the number of G
2
 phase cells was observed, whereas a decrease 
associated with an enhanced level of G
1
 arrest would be expected 
if cells were able to progress unimpeded through this section of 
the cell cycle. This suggested that genes involved in other aspects 
of cell cycle progression might be regulated by this NFκB subunit 
in these cells.
NFκB2 (p100/p52)-dependent regulation of PLK4 
expression
Based on the results in Figure 1, we therefore decided to 
examine other cell cycle-associated genes and, interestingly, 
discovered that NFκB2 depletion in U2OS cells resulted in 
downregulation of several genes involved in centrosome dupli-
cation: PLK4, AuroraA, the PLK4 downstream regulator SAS6, 
and CDK2, all showing significant reductions in mRNA levels 
(Fig. 2A, also Fig. 1B). Since it is a major effector of centro-
some duplication with little being known about its transcrip-
tional regulation, we decided to focus the rest of this study on 
PLK4. We next confirmed that these results were not restricted 
to U2OS cells and importantly found that NFκB2 depletion also 
resulted in downregulation of PLK4 expression in Hela cells as 
well as primary, untransformed, and non-immortalized human 
dermal fibroblasts (Fig. 2B and C). We independently observed 
loss of PLK4 expression in a microarray analysis of human der-
mal fibroblasts treated with an NFκB2 siRNA (Alessio Iannetti 
and Neil Perkins, unpublished observation). Depletion of PLK4 
with a siRNA confirmed that it is required for the proliferation of 
U2OS cells, and that its loss likely contributes to the decrease in 
cell proliferation also seen upon treatment with siRNAs target-
ing NFκB2 (Fig. 2D). NFκB2 (p100/p52) regulation of PLK4 
expression is therefore a widespread effect and can be seen in cells 
regardless of their transformed status. However, it is worth not-
ing that we find that culture of cells in vitro frequently induces 
a basal level of alternative NFκB pathway activity and so these 
effects will likely be more restricted in vivo, where NFκB activity 
is more tightly controlled.
We were next interested in whether these effects were restricted 
to NFκB2 activity. Analysis of data from a genome-wide analysis 
of c-Rel-dependent gene expression in T cells revealed PLK4 as 
a potential target gene, although this was not validated in the 
study.22 We used siRNAs targeting each NFκB subunit and 
found that all resulted in reduced PLK4 levels, with c-Rel deple-
tion having the strongest effect (Fig. 2E). All siRNAs have been 
previously published and validated,6,7,10 with western blot analy-
sis confirming their effect on protein expression (not shown). 
In addition, a siRNA targeting all NFκB subunits simultane-
ously (siRNA Pan-NFκB)23 was used to validate these effects. 
Targeting NFκB in this manner also reduced PLK4 mRNA and 
protein levels (Fig. 2F and G). Therefore this data confirmed 
that all NFκB subunits can potentially regulate PLK4 expres-
sion but did not demonstrate whether these effects were direct 
or indirect.
NFκB regulates PLK4 promoter activity
To address the question of whether NFκB regulation of PLK4 
expression occurred through the PLK4 promoter, a luciferase 
reporter plasmid was created containing the genomic region 
from −3713 to +972 relative to the PLK4 transcription start site. 
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Consistent with the siRNA data in Figure 2, overexpression of all 
NFκB subunits was found to upregulate PLK4 promoter activ-
ity, with c-Rel and p50 having the stronger effects (Fig. 3A–C). 
Co-expression of NFκB subunits did not exhibit a strong com-
binatorial effect, but this probably reflects dimerization with 
endogenous NFκB.
NFκB directly binds to the PLK4 promoter
The luciferase assay data suggested that PLK4 could be a 
direct target of NFκB activity. To address this, we performed 
chromatin immunoprecipitation experiments, focusing initially 
on the binding of the p52 NFκB2 subunit. By sequence homol-
ogy, we identified a number of putative NFκB binding sites 
upstream and downstream of the PLK4 transcription initiation 
site (Fig. 4A). For technical reasons with the PCR, likely caused 
by the high A/T content of much of the PLK4 promoter, we were 
not able to examine binding to all putative NFκB binding sites. 
However, analysis was possible for the kB elements at −2634, 
−1947, and −1256. Using PCR primers targeting these regions 
we were able to observe p52 binding in U2OS cells 
that was inhibited upon NFκB2 siRNA depletion, 
confirming the specificity of this signal (Fig. 4B). 
Overexpression of HA-tagged p52 in Hela cells fol-
lowed by ChIP analysis with an anti-HA antibody, 
further validated p52 binding to the upstream 
region of the PLK4 promoter (Fig. 4B). Moreover, 
significantly reduced binding was observed when a 
DNA binding mutant of p526 was used in this assay 
(Fig. 4C).
We next used ChIP to analyze binding of all the 
NFκB subunits to the PLK4 promoter in U2OS 
cells. Consistent with our siRNA and luciferase 
assay data, this analysis revealed binding by all sub-
units to the PLK4 promoter but not to the GAPDH 
control promoter (Fig. 5A–G). Interestingly, the 
relative levels of binding varied depending on the 
region of the PLK4 promoter analyzed, indicating 
differential recruitment to different NFκB binding 
sites. It should be noted that due to differences with 
antibodies, relative levels of binding between differ-
ent NFκB subunits cannot be accurately quantified. 
Binding of NFκB subunits to the PLK4 promoter 
was also confirmed in HeLa cells (not shown), vali-
dating PLK4 as a direct NFκB target gene in other 
cell models.
The PLK4 core promoter is sufficient to confer 
NFκB responsiveness
To understand more about the significance of 
NFκB regulation of PLK4 expression, we examined 
the putative promoter of the murine PLK4 gene. By 
contrast with the human promoter, we could only 
observe putative NFκB binding sites in the region of 
the core promoter and downstream of the transcrip-
tion start site (Fig. 6A). Of these, only a few were 
conserved between mouse and human. Nonetheless, 
ChIP analysis in immortalized mouse embryonic 
fibroblasts (MEFs) confirmed NFκB binding to the 
mouse PLK4 promoter (Fig. 6B). Use of nfkb2−/− MEFs demon-
strated the specificity of the p52 ChIP signal. Interestingly, in 
nfkb2−/− MEFS, the absence of p52 binding appears to be com-
pensated for by increased levels of binding of other NFκB sub-
units, correlating with higher levels of PLK4 mRNA in these cells 
(Fig. 6C). This data implied that the core region of the PLK4 
promoter might be sufficient to confer NFκB responsiveness. 
We therefore performed a deletion analysis of the human PLK4 
promoter luciferase plasmid to produce a truncated form of the 
promoter from −330 to +259 relative to the transcription start 
site, thus removing many of the putative kB elements (Fig. 6D). 
Interestingly, with some minor differences, this plasmid was still 
responsive to overexpressed NFκB subunits (Fig. 6E). Although 
it is well established that transiently transfected reporter plasmids 
do not recapitulate all the elements of endogenous gene regula-
tion, this data suggests a modulatory role for the distal NFκB 
sites and reveals that the PLK4 core promoter region alone is suf-
ficient for NFκB regulation.
Figure  1. Regulation of cyclin/CDK expression by NFκB2 (p52/p100). (A) p52/p100 
depletion results in reduced cells in S phase. U2oS cells were subjected to transient 
transfection using a control or NFκB2 siRNA for 48 h. DNA profile after siRNA trans-
fection in U2oS cells was analyzed by flow cytometry. (B and C) p52/p100 depletion 
affects the expression of cyclin and CDK genes. U2oS cells were subjected to transient 
transfection for 48h using a control or NFκB2 siRNA. the expression of genes involved 
cell cycle progression was analyzed for mRNA expression by qpCR (B) or for protein lev-
els by western blot (C) Results are the average of at least 3 independent experiments, 
and bars show the standard error. *P < 0.05 ; **P < 0.01; ***P < 0.001; ****P < 0.0001.
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Long-term depletion of NFκB2 results in defects in centro-
some structure
We were unable to visualize effects on centrosome duplication 
and structure resulting from short-term depletion of NFκB sub-
units using siRNA (not shown). At least in part this may result 
from other effects on the cell cycle and proliferation, resulting in 
a failure to progress through S-phase, where centrosome dupli-
cation is performed. However, we have found that long-term 
depletion of NFκB2 in U2OS cells, through the creation of cells 
lines stably expressing an shRNA, results in cells that overcome 
Figure 2. NFκB regulates pLK4 expression. (A) p52/p100 depletion regulates the expression of various genes involved in centrosome duplication. U2oS 
cells were subjected to transient transfection for 48 h using a control or NFκB2 siRNA. the mRNA expression of various genes involved in centrosome 
duplication was analyzed by qpCR. (B and C). p52/p100 depletion leads to reduced pLK4 expression. Hela cells (B) or dermal fibroblasts (C) were sub-
jected to transient transfection using a control, or NFκB2 siRNA and pLK4 mRNA expression was analyzed by qpCR. (D) p52/p100 and pLK4 depletion 
inhibits cell proliferation. U2oS cells were subjected to transient transfection using a control, NFκB2, or pLK4 siRNAs as indicated. Cell proliferation was 
then analyzed using the Mtt assay 54 h after initial transfection (D0) and then 24, 48, and 72 h after this (D1, D2 and D3). (E–G). Depletion of all NFκB 
subunits regulates the expression of pLK4 in U2oS cells. U2oS cells were subjected to transient transfection for 48 h using a control or siRNAs targeting 
all NFκB subunits either singly (D) or together using a pan-NFκB siRNA (E and F). pLK4 mRNA expression was analyzed by qpCR (D and E) or western blot 
(F). mRNA expression (A–E) was analyzed by quantitative pCR, compared with a housekeeper gene (GApDH) and related to the expression with siRNA 
control. Results are the average of at least 3 independent experiments and bars show the standard error. *P < 0.05 ; **P < 0.01; ***P < 0.001; ****P < 0.0001.
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Figure  3. NFκB regulates the pLK4 promoter activity. (A–C) 
overexpression of NFκB subunits increases pLK4 promoter activity. 
U2oS cells were transiently transfected with 1 μg of the full-length pLK4 
promoter luciferase plasmid and 1 μg of either individual RSV NFκB sub-
unit expression plasmids or the indicated combinations. Results are the 
average of at least 3 independent experiments, and bars show the stan-
dard error. *P < 0.05 ; **P < 0.01; ***P < 0.001; ****P < 0.0001
Figure 4. p52 specifically binds to multiple sites on the pLK4 promoter. 
(A) Schematic representation of the various putative κB sites identified 
in the human pLK4 promoter, with their sequences below. (B) p52 bind-
ing on the pLK4 promoter is reversible. U2oS cells were subjected to 
transient siRNA transfection, with either control or NFκB2 siRNA. After 48 
h, the cells were processed for ChIp analysis. (C) exogenous p52 binds the 
pLK4 promoter. Hela cells were subjected to transient DNA transfection, 
with plasmids coding for exogenous Ha tagged p52 or the p52 binding 
mutant (DBM). After 48 h, the cells were processed for ChIp analysis. 
Results are the average of at least 3 independent experiments, and bars 
show the standard error.
the proliferative block, although they only survive for a limited 
number of passages. Using electron microscopy, we analyzed cen-
trosome structure in these cells. Very few centrosomes could be 
identified in these cells, and those that could be observed did not 
have the normal appearance seen with cells expressing a control 
shRNA (Fig. 7). This outcome probably results from a combina-
tion of effects resulting from depletion of NFκB2 in addition to 
PLK4. Nonetheless, it establishes a functional link between NFκB 
activity and the correct duplication and structure of centrosomes.
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Discussion
Appropriate PLK4 expression is critical for normal centrosome 
duplication and correct cell cycle progression. Too much PLK4 
results in amplification of centrosomes,17 while its depletion 
reduces centriole number.16 NFκB regulation of PLK4 expression 
thereby provides a mechanism to link inflammatory and immune 
signaling to centrosome duplication and mitosis. Moreover, we 
also observed NFκB regulation of the SAS6, CDK2, and Aurora 
A genes, although in these cases we did not determine by ChIP 
analysis if these effects were direct. SAS6 downregulation has 
been also shown to inhibit centriolar duplication,24 whereas 
AuroraA siRNA treatment of Hela cells resulted in incorrect cen-
triolar separation, incomplete cytokinesis, and chromosome mis-
alignment on the metaphasic plate.25 PLK4 works in concert with 
the cyclin-dependent kinase CDK2 and SAS6 to ensure correct 
centrosome duplication.15 These data suggest a coordinated regu-
latory pathway linking NFκB function to mitotic regulation that 
is consistent with previous data linking IKKα and IKKβ to this 
process.11,12 However, it is interesting to note that PLK4 has also 
been shown to be required for a TLR induced anti-viral response, 
involving the TNFAIP2 gene,26 which has previously been shown 
to be an NFκB target.27 This pathway may therefore have a dis-
tinct role facilitating NFκB-driven innate immune responses.
Regulation of effector kinases provides a powerful mechanism 
through which signaling pathways can crosstalk and have wide-
spread cellular effects. Under normal physiological conditions, 
these effects are balanced to ensure appropriate cell proliferation. 
These effects were observed in cultured cells in vitro, where a 
basal level of NFκB activity is typically observed. In vivo, it is 
likely that regulation of centrosomal duplication by NFκB occurs 
only in specific circumstances. Similar to NFκB regulation of 
other genes regulating cell proliferation such as Cyclin D1 and 
c-Myc, it is probable that other transcription factors and signal-
ing pathways regulate PLK4 expression in different contexts.
NFκB regulation of PLK4 also provides a potential route 
through which aberrant activation of NFκB in cancer, either 
through inflammation or oncogene activation, could lead to 
genomic instability. We, and others, have previously documented 
crosstalk between the NFκB and the p53 tumor suppressor path-
ways.3 It is interesting to note that p53 has recently been shown to 
downregulate PLK4 expression.18,19 Moreover, p53 has previously 
been shown to repress expression of PLK1,28 a kinase related to 
PLK4 that is also involved in G
2
/M transition, and that can also 
be an NFκB target gene.29 These data suggest that regulation of 
these kinases provides another route of potentially antagonistic 
crosstalk between the NFκB and p53 pathways.
In analyzing the PLK4 promoter, we identified a number 
of putative NFκB binding sites. ChIP analysis suggested that 
NFκB complexes may differentially occupy both the distal and 
proximal promoter binding sites. However, this type of analysis 
can also produce a positive signal if DNA looping is occurring 
between different promoter regions. Indeed, when we examined 
the mouse promoter, the only sites conserved were in the region of 
the core promoter and immediately downstream of the transcrip-
tion start site. Furthermore, deletion analysis of the promoter in 
luciferase assays suggested that the core promoter is sufficient to 
confer NFκB regulation. Therefore, it is plausible that the core 
promoter represents the site of direct NFκB interaction, and the 
signals seen with primers to upstream regions result from DNA 
looping effects. Alternatively, regulation of the human gene 
may be more complex than that of the mouse, and this could be 
reflected by the presence of multiple NFκB binding sites.
We have previously observed differential NFκB subunit occu-
pancy at target gene promoters at different cell cycle stages.7 
Furthermore, this is associated with differential recruitment of 
coactivators and co-repressors. For example, regulation of Cyclin 
D1 expression in early passage U2OS cells involves p52-depen-
dent recruitment of coactivators in G
1
 phase followed by a switch 
to p52-dependent recruitment of co-repressors in G
2
 phase.7 It is 
very likely that similar regulation is occurring with PLK4, and 
that the recruitment of all NFκB family members to the pro-
moter may reflect a more complex, cell cycle-dependent regu-
lation with differential effects being exerted in G
1
, S, and G
2
 
phases. Assessing the contribution of the different κB sites will 
be technically challenging. It is unlikely that mutation of these 
sites within the PLK4 promoter luciferase plasmid will be infor-
mative, as such reporters frequently fail to recapitulate complex 
mechanisms of gene regulation requiring regulation of chromatin 
structure and DNA looping. However, informative clues might 
be obtained through ChIP-Seq analysis of cells at different cell 
cycle stages to examine differential recruitment of NFκB sub-
units (and their modified forms) to different κB elements.
NFκB responds to an incredibly diverse set of stimuli in all cell 
types. It is a key component of the ability of an organism to adapt 
to and survive infection and stress. Taken together with previous 
results from this and other laboratories, this study adds to the 
data supporting cell cycle regulation as being a vital component 
of the NFκB signaling. Integrating cell division and proliferation 
with NFκB function will be required for an appropriately coor-
dinated cellular response. However, when NFκB becomes aber-
rantly regulated in disease, particularly cancer, these cell cycle 
target genes provide a pathway that can lead to increased genomic 
instability and uncontrolled proliferation.
Materials and Methods
Cell growth, siRNA, and DNA transfection
U2OS cells, Hela cells, H1299 cells, wild-type, and nfkb2−/− 
MEF were maintained at 37 °C, 5% CO
2
 in DMEM (Lonza), 
with 10% FBS (Life Technologies), and antibiotics.
RNAi transfection was performed in cells at 30% confluency, 
mixing 5 nM siRNA with Interferin reagent (Polyplus) according 
manufacturer’s conditions. Forty-eight hours post-transfection, 
cells were harvested and processed as required. DNA transfection 
for luciferase assays were performed using 2 μg DNA with PEI 
using manufacturer’s conditions and left to rest for 48 h.
Flow cytometry
DNA profile was analyzed by flow cytometry. Forty-eight 
hours after siRNA transfection, cells were detached, PBS washed, 
and pelleted. Cells were then resuspended in PBS containing 50 
μg/ml of propidium iodide and 50 μg/ml of RNase A. Cells 
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Figure 5. the pLK4 promoter is a NFκB target. U2oS cells were fixed by paraformaldehyde and processed for a ChIp assay, using antibodies against dif-
ferent NFκB subunits, using acetylated histone H3 (AcH3) as a positive and IgG as a negative control. (A) Recruitment of the NFκB subunits to the pLK4 
promoter. pCR was performed with primers for the pLK4 promoter transcription initiation site. (B–G) Quantification of NFκB recruitment to the pLK4 
promoter. qpCR were performed after ChIp analysis on the indicated NFκB subunits and binding sites (initiation site, prpLk4-2634, prpLK4-1947, and 
prpLK4-1256) together with control promoter region (GApDH). Results are expressed as binding relative to the IgG control (which is normalized to 1) and 
is the average of at least 3 independent experiments. Bars show the standard error. *P < 0.05 ; **P < 0.01; ***P < 0.001; ****P < 0.0001
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were then processed for analysis for cell cycle distribution with 
a BD FACSCanto II (6c) (Becton Dickinson) and FlowJo ana-
lyzing software. Five thousand cells were analyzed to determine 
the DNA profile for each condition. Results shown are averages 
derived from 3 separate experiments, and error bars indicate the 
standard error.
MTS proliferation assay
U2OS cells in 24-well plates were transfected in dupli-
cate with siRNAs, using the previously described conditions. 
Twenty-four hours later, the cells were washed, detached with 
trypsin-EDTA, and the duplicates were combined in the same 
well of a 6-well plate. The next day, cells were once again trans-
fected with siRNA using the previously described conditions. 
Twenty-four hours later, the cells were washed, detached with 
trypsin-EDTA, counted, and replated in 96-well plates at a con-
centration of 2000 cells per well. Six hours later, the prolifera-
tion at day = 0 (D0) was determined by MTS assay (Promega 
CellTiter 96® AQueous One Solution Cell Proliferation Assay) 
and a 96-well plate reader (POLARstar Omega, BMG 
Labtech). Readings were then taken over 3 d sequentially 
24 h after the previous one (D1, D2, D3). Results shown 
are averages derived from 3 separate experiments, and 
error bars indicate the standard error.
Luciferase assays
The PLK4 promoter luciferase reporter plasmid was 
created by Dundee Cell Products. After PBS washes, 
cells were lysed with Passive Lysis Buffer (PLB, Promega) 
and centrifuged at 19 350 g for 5 min. The supernatant 
was then assayed using the Luciferase Assay System 
(Promega) in a Lumat LB9507 luminometer (Bethold 
Technologies). Results were normalized to protein con-
centration, and all experiments were performed a mini-
mum of 3 times before calculating means and standard 
error as shown in the figures.
Chromatin immunoprecipitation (ChIP)
All cell lines used for ChiP assay, either grown to 70% 
confluency or analyzed 48 h after transfection, were 
cross-linked with 1% formaldehyde at room temperature 
for 10 min. Media was removed, and cells were incubated 
with cold glycine 0.125 M for 3 min at room temperature 
and washed twice with cold PBS, before being scraped 
into 0.5 mL of RIPA buffer (0.1% SDS, 1% Triton, 0.5% 
deoxycholate, 0.5% NP40, 50 mM Tris-HCl pH 7.5, 150 
mM NaCl, 50 µg/ml PMSF, 1 μg/ml leupeptin, 1 μg/ml 
aprotinin, 1 µg/ml pepstatin, 50 µg/ml Na
3
VO4, 50 µg/
ml NaF) and left on ice for 10 min. Samples were then 
sonicated on ice 7 times. Each sonication was for 30 s 
with a 30 s gap between each sonication. Supernatants 
Figure 6. NFκB regulation of pLK4 is conserved in mouse cells. 
(A) Schematic representation of the various putative κB sites 
identified in the mouse pLK4 promoter. Sequences below show 
the conservation of sequences between the mouse and human 
genes. (B) Recruitment of NFκB subunits to the mouse pLK4 pro-
moter. Wild-type and nfkb2 −/− MeFs were fixed with formalde-
hyde and processed for ChIp analysis, using antibodies against 
the indicated NFκB subunits, using RNApolII as a positive and 
IgG as a negative control. pCR was performed with primers for 
the initiation site. (C) nfkb2 −/− MeFs show elevated levels of pLK4 
mRNA. Wild-type and nfkb2 −/− MeFs were analyzed by qpCR to 
determine the basal levels for pLK4 expression. (D) Schematic 
representation of the full-length human pLK4 promoter lucif-
erase reporter and its core promoter mutant. (E) the pLK4 core 
promoter is sufficient to confer NFκB responsiveness. U2oS cells 
were transiently transfected with 1 μg of the full-length or core 
pLK4 promoter luciferase plasmids and 1 μg of either individual 
RSV NFκB subunit expression plasmids. Results are the average 
of at least 3 independent experiments, and bars show the stan-
dard error. *P < 0.05 ; **P < 0.01; ***P < 0.001; ****P < 0.0001
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were recovered by centrifugation at 12 000 rpm in an eppendorf 
microfuge for 10 min at 4 °C before being diluted 1:1 in dilution 
buffer (1% Triton, 2 mM EDTA, 20 mM Tris-HCl pH 8.1, 150 
mM NaCl supplemented with 0.1% NP40, protease and phos-
phatase inhibitors). Samples were then precleared for 2 h at 4 °C 
with sheared salmon sperm DNA (1 μg/ml) and 20 μl of protein 
A and G-agarose beads. At this stage, 20 μl of the material was 
kept as input material. Immunoprecipitations were performed 
overnight with specific antibodies (2 μg). The immune com-
plexes were captured by incubation with 20 μl of protein A and 
G-agarose beads and salmon sperm DNA (1 μg/ml) for 1 h at 4 
°C. The immunoprecipitates were washed sequentially for 5 min 
each at 4 °C in TSE 1 (0.1% SDS, 1% Triton, 2 mM EDTA, 20 
mM Tris-HCl pH 8.1,150 mM NaCl), TSE 2 (0.1% SDS, 1% 
Triton, 2 mM EDTA, 20 mM Tris-HCl pH 8.1500 mM NaCl), 
Buffer 3 (250 mM LiCl, 1% NP40, 1% deoxycholate, 1 mM 
EDTA, 10 mM Tris-HCl pH 8.1), and TE buffer (1 mM EDTA, 
10 mM Tris-HCl pH = 8.1). Beads were then eluted with 500 μl 
of Elution buffer (1% SDS,100 mM NaHCO3).
To reverse the crosslinks, samples, including “Input”, were 
incubated at 65 °C overnight in a waterbath with 0.2 M NaCl. 
DNA was ethanol precipitated following Phenol-Chloroform 
extraction. For PCR, 5 μl of DNA was used from an 80 μl DNA 
preparation and subjected to 40 cycles of PCR amplification.
For all ChIP results shown are averages derived from 3 sepa-
rate experiments, and error bars indicate the standard error.
Quantitative RNA analysis
Total RNA was extracted with PeqLab gold total RNA extrac-
tion kit according to the manufacturer’s directions. For reverse 
transcriptase PCR (RT-PCR), 1 μg RNA sample were tran-
scribed with Quantitect Reverse Transcription Kit (QIAgen). 
The cDNA stock was diluted by 200 and 5 µl was used for PCR 
with GoTaq flexi DNA-polymerase (Promega).
Quantitative PCR data was generated on a Rotor-Gene Q 
(Qiagen) using the following experimental settings: hold, 95 °C 
for 5 min; cycling, (95 °C for 20 s; 58 °C for 20 s; 72 °C for 20 s 
with fluorescence measurement) × 40; melting curve, 50–99 °C 
with a heating rate of 1 °C every 5 s. All values were calculated 
relative to untreated levels and normalized to GAPDH levels 
using the Pfaffl method.30 Each RNA sample was assayed in trip-
licate, and the results shown are averages derived from 3 separate 
experiments with error bars indicating the standard error.
Creation of NFκB2 shRNA stable cell lines
NFκB2 (p100/p52) shRNA and control plasmids used to 
generate stable U2OS cell lines were created using the pSilencer 
plasmid (Ambion) using a 5′ BamH1 site and a 3′ HindIII site. 
U2OS cells were seeded at 8 × 105 cells/ml in a 6-well dish the 
night before transfection. The next day cells were transfected 
with 1.5 µg of pooled NFκB2 (p100/p52) shRNA expressing 
plasmids or the control plasmid using Genejuice transfection 
reagent (Novagen), according to the manufacturer’s instruc-
tions. Forty-eight hours post-transfection, cells were selected 
with Hygromycin B. Cells were from a pool of stable clones 
that emerged in the weeks after selection. NFκB2 (p100/p52) 
shRNA and control shRNA sequences have been published 
previously.6
Electron microscopy
Cells were fixed in 2.5% glutaraldehyde in 0.1 M sodium caco-
cylate buffer. Post-fixation was performed in 1% osmium tetrox-
ide in 0.1 M cacodylate. Cells were washed in buffer before being 
dehydrated in graded ethanols to absolute alcohol and then over-
night in 1% uranyl acetate in absolute ethanol. This was followed 
by propylene oxide treatment for 2 × 15 min followed by 50:50 
propylene oxide:durcupan resin treatment overnight (Durcupan, 
Sigma). Propylene was evaporated for 2 h before addition of fresh 
resin for 3 to 4 h. Cells were placed into molds in fresh resin 
and polymerized at 60 °C for about 24 h. Sections were cut on a 
Leica Ultracut UCT ultramicrotome and collected on Pioloform 
coated 100 mesh copper grids. Sections were stained with uranyl 
acetate and Reynolds lead citrate and examined using a TecnaI 12 
Figure 7. p52/p100 depletion affects centrosome structure. (A) Western 
blot analysis of stable shRNA-expressing cells. (B) Centrosome structure 
was analyzed by electron microscopy in U2oS cells stably expressing 
NFκB2 (p52/p100) shRNA or a control shRNA.
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(FEI) electron microscope. Images recorded on Fuji digital plates 
and processed in a Ditabis plate scanner.
Antibodies
Antibodies used were: anti-p52/p100 (05-361 Millipore), anti-
RelB (4954S Cell Signaling), anti-β-Actin (A5441, Sigma), anti-
RelA (sc-372 Santa Cruz), anti-c-Rel (sc-71 Santa Cruz), anti-p50 
(06–886 Upstate), anti-PLK4 (3258S Cell Signaling), cyclin D1 
(556977 BD pharmingen), cyclin A (CC02 Calbiochem), cyclin 
E (sc-481 Santa Cruz), cyclin B1 (sc-752 Santa Cruz), CDK2 (sc-
6248 Santa Cruz), CDK4 (sc-260 Santa Cruz), CDK1 (CRUK 
antibodies).
Antibodies used in ChIP assay were: anti-p52/p100 (sc-848 
Santa Cruz), anti-RelB (sc-226 Santa Cruz), anti-RelA (sc-372 
Santa Cruz), anti-c-Rel (sc-71 Santa Cruz), anti-p50 (sc-114 
Santa Cruz), anti-AcHistone 3 (06-599 Millipore).
siRNAs
siRNA control, siRNA NFκB2, siRNA RelB, siRNA RelA, 
siRNA c-Rel, siRNA NFκB1, siRNA pan-NFκB described6,10,23
Oligonucleotides
RT-PCR (human)
NFκB2 For-GGGCAGACCAGTGTCATTGAG
Rev-CCATGCCGATCCAGCAGAG
RelB For-CATCGAGCTCCGGGATTGT
Rev-CTTCAGGGACCCAGCGTTGTA
RelA For – CTC-GGT-GGG-GAT-GAG-ATC-TTC
Rev- CCG-GTG-ACG-ATC-GTC-TGT-ATC
NFκB1 For – TCC-CAT-GGT-GGA-CTA-CCT-GG
Rev- ATA-GGC-AAG-GTC-AGG-GTG-C
c-Rel For – AGA GGG GAA TGC GTT TTA GAT ACA
Rev- CAG GGA GAA AAA CTT GAA AAC ACA
PLK4 For – GAT CAT TTG CTG GTG TCT A
Rev – ACC TCA TTT TGG ACT CTC TG
SAS6 For – GAA TGA GCA TTG AAC TAC A
Rev – GGT GAG TTA TCC AAA ATA GC
Cyclin A For – CGC TGG CGG TAC TGA AGT C
Rev – GAG GAA CGG TGA CAT GCT CAT
Cyclin B1 For – ATA-AGG-CGA-AGA-TCA-ACA-TGG-C
Rev – TTT-GTT-ACC-AAT-GTC-CCC-AAG-AG
Cyclin D1 For – CCA TTC CCT TGA CTG CCC GAG
Rev – GAC CAG CCT CTT CCT CCA C
Cyclin E For – TTA CCC AAA CTC AAC GTG CAA
Rev – GCT CAA GAA AGT GCT GAT CCC
CDK1 For – AAA CTA CAG GTC AAG TGG TAG CC
Rev – TCC TGC ATA AGC ACA TCC TGA
CDK2 For – ATC TCT CGG ATG GCA GTA
Rev – GTT GTG TAC AAA GCC AGA AAC
CDK4 For – AGA GTG TGA GAG TCC CCA ATG
Rev - CAA ACA CCA GGG TTA CCT TG
Centrin2 For – GAA CTG GCA CCA TAG ATG T
Rev – TTT CCT GTC CCT TCC TTA T
g-tubulin For – TAC AAC CCA GAG AAC ATC TA
Rev – CAT CTG CTT CTC GGT CTA T
AuroraA For – CACCACTTGGAACAGTCTATA
Rev - AATAACTCTCTTCGAATGACA
GAPDH For - GGTCGTATTGGGCGCCTGGTCACC
Rev - CACACCCATGACGAACATGGGGGC
RT-PCR (mouse)
NFκB2 For- CTA-ATG-TGA-ATG-CCC-GGA-CC
Rev - GAG-CAG-CAT-TTA-GCA-GCA-GAG
PLK4 For – AGG-AGA-AAC-TAA-TGA-GCA-CCA-CA
Rev – TGG-CTC-TCG-TGT-CAG-TCC-AA
GAPDH For – GCTACACTGAGGACCAGGTTG
Rev – GCCCCTCCTGTTATTATGGGG
ChIP (human)
prPLK4–2634 For – GCT-AGG-TTG-AAA-GGA-GCT-
CTC-AC
Rev – AGC-CCC-CTC-ATA-ATT-CAA-GG
prPLK4–1947 For – TTG-TGA-GAG-AGG-GGT-TTG-CT
Rev – ACA-TTT-GGA-GGC-ACG-TGA-TA
prPLK4–1256 For – GGA-ACA-ATT-GAC-AAA-TCG-
GAA-T
Rev – AAC-ATT-TTG-CCA-CAC-TTG-TTT-TT
prPLK4 initiation site For – TGG-CCC-CGA-AGT-CTA-
GAA-CC
Rev – CAG-GCT-CGG-CTC-TCT-AAA-CC
Primers for Cyclin D1 and GAPDH have been described6
ChIP (mouse)
mprPLK4 initiation site For - GCT ACG GTC AGT CGT 
ACA CTG
Rev - GTG ACG TCA GCA CAC TCT CCA C
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